Skip to main content

Research Repository

Advanced Search

The Clinical Effectiveness of Using a Predictive Algorithm to Guide Antidepressant Treatment in Primary Care (PReDicT): an open-label, randomised controlled trial

Browning, Michael; Bilderbeck, Amy C.; Dias, Rebecca; Dourish, Colin T.; Kingslake, Jonathan; Deckert, Jurgen; Goodwin, Guy M.; Gorwood, Philip; Guo, Boliang; Harmer, Catherine J.; Morriss, Richard; Reif, Andreas; Ruhe, Henricus G.; Van Schaik, Anneke; Simon, Judit; Sola, Victor Perez; Veltman, Dick J.; Elices, Matilde; Lever, Anne G.; Menke, Andreas; Scanferla, Elisabetta; St�blein, Michael; Dawson, Gerard R.

The Clinical Effectiveness of Using a Predictive Algorithm to Guide Antidepressant Treatment in Primary Care (PReDicT): an open-label, randomised controlled trial Thumbnail


Authors

Michael Browning

Amy C. Bilderbeck

Rebecca Dias

Colin T. Dourish

Jonathan Kingslake

Jurgen Deckert

Guy M. Goodwin

Philip Gorwood

BOLIANG GUO BOLIANG.GUO@NOTTINGHAM.AC.UK
Associate Professor

Catherine J. Harmer

RICHARD MORRISS richard.morriss@nottingham.ac.uk
Professor of Psychiatry and Community Mental Health

Andreas Reif

Henricus G. Ruhe

Anneke Van Schaik

Judit Simon

Victor Perez Sola

Dick J. Veltman

Matilde Elices

Anne G. Lever

Andreas Menke

Elisabetta Scanferla

Michael St�blein

Gerard R. Dawson



Abstract

Depressed patients often do not respond to the first antidepressant prescribed, resulting in sequential trials of different medications. Personalised medicine offers a means of reducing this delay, however the clinical effectiveness of personalised approaches to antidepressant treatment has not previously been tested. We assessed the clinical effectiveness of using a predictive algorithm, based on behavioural tests of affective cognition and subjective symptoms, to guide antidepressant treatment. We conducted a multi-centre, open-label, randomised controlled trial in 913 medication-free depressed patients. Patients were randomly assigned to have their antidepressant treatment guided by a predictive algorithm or treatment as usual (TaU). The primary outcome was response of depression symptoms, defined as a 50% or greater reduction in baseline score of the QIDS-SR-16 scale, at week 8. Additional prespecified outcomes included symptoms of anxiety at week 8, and symptoms of depression and functional outcome at weeks 8, 24 and 48. The response rate of depressive symptoms at week 8 in the PReDicT (55.9% ) and TaU (51.8% ) arms did not differ significantly (odds ratio: 1.18 (95% CI: 0.89-1.56), p=0.25). However, there was a significantly greater reduction of anxiety at week 8 and a greater improvement in functional outcome at week 24 in the PReDicT arm. Use of the PReDicT test did not increase the rate of response to antidepressant treatment estimated by depressive symptoms, but did improve symptoms of anxiety at week 8 and functional outcome at week 24. Our findings indicate that personalisation of antidepressant treatment may improve outcomes in depressed patients.

Journal Article Type Article
Acceptance Date Jan 27, 2021
Online Publication Date Feb 26, 2021
Publication Date Jun 1, 2021
Deposit Date Jan 29, 2021
Publicly Available Date Aug 27, 2021
Journal Neuropsychopharmacology
Print ISSN 0893-133X
Electronic ISSN 1740-634X
Publisher Nature Publishing Group
Peer Reviewed Peer Reviewed
Volume 46
Pages 1307–1314
DOI https://doi.org/10.1038/s41386-021-00981-z
Public URL https://nottingham-repository.worktribe.com/output/5274659
Publisher URL https://www.nature.com/articles/s41386-021-00981-z

Files






You might also like



Downloadable Citations